← Back to Clinical Trials
Recruiting NCT05237817

NCT05237817 Association Between Stroke and Adrenal Incidentalomas

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05237817
Status Recruiting
Phase
Sponsor Xuanwu Hospital, Beijing
Condition Stroke
Study Type OBSERVATIONAL
Enrollment 2 participants
Start Date 2021-04-01
Primary Completion 2022-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2 participants in total. It began in 2021-04-01 with a primary completion date of 2022-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke. Stroke is a diseases which could cause of disability and death worldwide. In clinical practice, detailed information about the association between stroke and AIs is not available. In this study, the investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs.

Eligibility Criteria

Inclusion Criteria: * stroke disease , such as Cerebral infarction、Intracerebral hemorrhage and Subarachnoid hemorrhage. Exclusion Criteria: * presence of metastatic cancer; * AIs smaller than 1 cm; * nonadenoma lesions, such as myelolipomas,hemorrhages, and cysts; * oral glucocorticoid treatment with more than single doses in the past 3 months; * use of inhaled steroids or medication affecting dexamethasone metabolism; * systemic estrogen treatment.

Contact & Investigator

Central Contact

Hao Yan, Dr.

✉ yanhurology@qq.com

📞 +86-13651341058

Principal Investigator

Tong W Ou, Dr.

STUDY DIRECTOR

Department of Urology, Xuanwu Hospital, Capital Medical University

Frequently Asked Questions

Who can join the NCT05237817 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05237817 currently recruiting?

Yes, NCT05237817 is actively recruiting participants. Contact the research team at yanhurology@qq.com for enrollment information.

Where is the NCT05237817 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT05237817 clinical trial?

NCT05237817 is sponsored by Xuanwu Hospital, Beijing. The principal investigator is Tong W Ou, Dr. at Department of Urology, Xuanwu Hospital, Capital Medical University. The trial plans to enroll 2 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology